title: Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach?
abstract: Gastric cancer is one of the most prevalent and deadliest forms of cancer worldwide. Even though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy may improve outcomes compared with surgery alone, the optimal combination of treatment modalities remains controversial. While European and North American trials established perioperative chemotherapy and adjuvant chemoradiation regimens for gastric cancer, Asian countries have focused on the use of adjuvant chemotherapy. This review summarizes results from contemporary randomized controlled trials and meta-analyses to elucidate the relative merits of each treatment approach.
authors.affiliation: School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: Xuguang
authors.initials: X
authors.lastname: Chen
authors.forename: Jennifer R
authors.initials: JR
authors.lastname: Eads
authors.forename: John B
authors.initials: JB
authors.lastname: Ammori
authors.forename: Aryavarta M
authors.initials: AM
authors.lastname: Kumar
authors.forename: Tithi
authors.initials: T
authors.lastname: Biswas
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Dorth
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*